TITLE

UCB COMPLETES MUTUAL RECOGNITION PROCEDURE FOR EQUASYM XL

PUB. DATE
July 2006
SOURCE
Worldwide Biotech;Jul2006, Vol. 18 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the completion by UCB of the European Mutual Recognition Procedure for Equasym XL for use in the treatment of the symptoms of attention deficit hyperactivity disorder (ADHD). Commitment by the company to minimizing the impact of ADHD on children according to Troy Troy Cox, president CNS Operations at UCB; Main symptoms of ADHD; Background on the efficacy of Equasym XL against ADHD.
ACCESSION #
21352196

 

Related Articles

  • Vyvanse OK'd for Peds ADHD Maintenance.  // MPR - Pediatricians' Edition;Fall/Winter2013, Vol. 24 Issue 2, pA6 

    The article reports on the approval of yvanse capsule for maintenance treatment of attention-deficit hyperactivity disorder (ADHD) in adolescents and children aged ≥ six years old.

  • Vyvanse Gains Approval.  // Monthly Prescribing Reference;Mar2012, Vol. 28 Issue 3, pA-19 

    The article offers information on the approval of the drug Vyvanse made by Shire PLC for the treatment of adults with attention deficit hyperactivity disorder (ADHD).

  • ADHD Update.  // PharmaWatch: CNS;Jun2010, Vol. 9 Issue 6, p14 

    The article offers updates on issue related to pharmaceutical industry. Shire Pharmaceuticals Group PLC announces the approval of the change to the prescribing information for its once-daily attention deficit hyperactivity disorder (ADHD) treatment Vyvanse capsules CII. Shire receives a notice...

  • ADHD drug given Schedule II classification.  // Drug Topics;5/21/2007, Vol. 151 Issue 10, 0 p10 

    The article reports that attention-deficit hyperactivity disease (ADHD) prodrug lisdexamfetamine dimesylate with a brand name Vyvanse from Shire Pharmaceuticals Group PLC will be considered a Schedule II substance, according to the U.S. Drug Enforcement Association. The consideration of the...

  • ADHD Update.  // PharmaWatch: CNS;Oct2010, Vol. 9 Issue 10, p11 

    The article offers medical briefs on attention deficit/hyperactivity disorder (ADHD) in the U.S. Actavis, receives approval from the Food and Drug Administration (FDA) to market Atomoxetine HCI capsules for the treatment of ADHD. Sun Pharmaceutical Industries announces that FDA has granted its...

  • FDA Approves New ADHD Agent.  // Journal of Psychosocial Nursing & Mental Health Services;Aug2005, Vol. 43 Issue 8, p14 

    The article reports on the approval of Focalin XR by the U.S. Food and Drug Administration for treating attention-deficit hyperactivity disorder in adults, adolescents and children. The drug is said to be well tolerated and has not caused changes in the weight or vital signs of patients. Its...

  • Focalin XR 30mg OK'd.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA34 

    The article reports on the approval of Focalin, a 30milligram dosage strength of the attention deficit hypractivity disorder (ADHD) drug, by the U.S. Food and Drug Administration.

  • ADHD Update.  // PharmaWatch: CNS;Mar2012, Vol. 11 Issue 3, p14 

    The article reports on the U.S. Food and Drug Administration (FDA) approval received by Shire PLC for its prescription medication Vyvanse lisdexamfetamine dimesylate capsules for adults with attention-deficit hyperactivity disorder (ADHD). The approval is based on the study designed to evaluate...

  • Intuniv approved for ADHD.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA7 

    The article reports on the approval of selective alpha2A adrenergic receptor antagonist Intuniv as a treatment for attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to 7 years old. It states that the drug is not a controlled substance and is available in tablet...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics